Front. Immunol. Frontiers in Immunology Front. Immunol. 1664-3224 Frontiers Media S.A. 10.3389/fimmu.2025.1764419 Correction Correction: Obinutuzumab in systemic lupus erythematosus: a real-world experience WuChunmei 1 † Conceptualization Writing – review & editing Funding acquisition Writing – original draft Data curation Validation Methodology Formal analysis WangYinglu 1 † Methodology Investigation Visualization Software Writing – original draft Data curation Formal analysis ChenShenshen 1 Data curation Writing – review & editing LinYanwei 1 Data curation Writing – review & editing DuFang 1 Supervision Writing – review & editing Data curation WangXiaodong 1 Writing – review & editing Supervision Data curation ChenSheng 1 Writing – review & editing Supervision LuLiangjing 1 Supervision Writing – review & editing YeShuang 1 Supervision Writing – review & editing Conceptualization Project administration DingHuihua 1 * Methodology Writing – review & editing Supervision Conceptualization Resources FuQiong 1 2 * Funding acquisition Methodology Formal analysis Writing – original draft Supervision Conceptualization Resources Investigation Writing – review & editing Department of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China Shanghai Immune Therapy Institute, Shanghai, China Correspondence: Huihua Ding, dinghuihua@outlook.com; Qiong Fu, fuqiong5@163.com

These authors are co-first authors and contribute equally to this paper

 16 12 2025 2025 16 1764419 10 12 2025 11 12 2025 10 12 2025 Copyright © 2025 Wu, Wang, Chen, Lin, Du, Wang, Chen, Lu, Ye, Ding and Fu. 2025 Wu, Wang, Chen, Lin, Du, Wang, Chen, Lu, Ye, Ding and Fu https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. A Correction on Obinutuzumab in systemic lupus erythematosus: a real-world experience By Wu C, Wang Y, Chen S, Lin Y, Du F, Wang X, Chen S, Lu L, Ye S, Ding H and Fu Q (2025) Front. Immunol. 16:1702550. doi: 10.3389/fimmu.2025.1702550 systemic lupus - erythematosus obinutuzumab biologics real world study B cell depletion section-at-acceptance Autoimmune and Autoinflammatory Disorders : Autoimmune Disorders

There was a mistake in Table 1 as published. The percentage given for the ‘Relapsing’ column was erroneously written as “27 (55.4)”. This has been corrected to read “27 (48.2)”. The percentage given for the “musculoskeletal involvement” column was erroneously written as “9 (16.1)”. This has been corrected to read “10 (17.9)”. The corrected Table 1 appears below.

Baseline characteristics of SLE patients treated with obinutuzumab.

SLE Patients (n=56)
Epidemiologic features
 Female, n (%) 45 (80.3)
  Disease duration at first treatment, mean ± SD, (months) 48.52 ± 49.32 (0.3-168)
  Disease state, n (%)
   New-onset 20 (35.7)
   Relapsing 27 (48.2)
   Refractory 4 (7.1)
   Maintenance 5 (8.9)
 Age at obinutuzumab treatment, mean ± SD, (years) 30.98 ± 12.45 (13-65)
Clinical features, n (%)
  Fever 15 (26.8)
  Mucocutaneous involvement 20 (35.7)
  Musculoskeletal involvement 10 (17.9)
  Serositis 19 (33.9)
  Hematologic abnormalities 30 (53.6)
   Autoimmune hemolytic anemia 12 (21.4)
    Hemoglobin level≦60g/L 3 (25.0)
   Immune thrombocytopenia 15 (26.8)
    Plate level≦30×109/L 5 (33.3)
   Leukocytopenia 5 (8.9)
  Lupus nephritis 15 (26.8)
   24-hour urine protein, mean ± SD, (g/24h) 2.28 ± 0.49 (0.67-6.09)
   Serum creatinine, mean ± SD, (µmol/L) 83.83 ± 41.29 (32-185)
  Neuropsychiatric lupus 18 (32.1)
  Gastrointestinal vasculitis 5 (8.9)
  Pulmonary hypertension 4 (7.1)
  Thrombotic microangiopathy 4 (7.1)
  Myocardial involvement 2 (3.6)
  Antiphospholipid syndrome
   Deep venous thrombosis 7 (12.5)
   Cerebral infraction 3 (5.4)
   Pulmonary embolism 1 (1.8)
Serologic characterization
  WBC, mean ± SD, (×109/L) 8.10 ± 4.29 (1.02-21.72)
  Hb, mean ± SD, (g/L) 104.89 ± 26.06 (51.00-154.00)
  PLT, mean ± SD, (×109/L) 167.71 ± 120.57 (2.00-494.00)
  C3, mean ± SD, (g/L) 0.65 ± 0.28 (0.19-1.34)
  C4, mean ± SD, (g/L) 0.12 ± 0.10 (0.02-0.66)
  IgA, mean ± SD, (g/L) 2.57 ± 1.26 (0.27-6.55)
  IgM, mean ± SD, (g/L) 1.03 ± 0.70 (0.21-3.00)
  IgG, mean ± SD, (g/L) 16.7 ± 8.9 (6.15-53.90)
  Anti-dsDNA (ELASA), mean ± SD, (IU/mL) 167.90 ± 131.26 (22.46-505.06)
  Anti-dsDNA (RIA), mean ± SD, (IU/mL) 51.66 ± 35.32 (4.96-100)
  Antinuclear antibody positivity, n (%) 56 (100.0)
  Anti-SSA positivity, n (%) 28 (50.0)
  Anti-Ro52 positivity, n (%) 23 (41.1)
  Anti-SSB positivity, n (%) 7 (12.5)
  Anti-U1RNP positivity, n (%) 20 (35.7)
  Anti-Sm positivity, n (%) 7 (12.5)
  Anti-Rib-P positivity, n (%) 15 (26.8)
  Anti-Histone positivity, n (%) 12 (21.4)
  Antiphospholipid antibody positivity, n (%) 37 (66.1)
  B lymphocyte levels
   B lymphocyte percentage, mean ± SD, (%) 17.76 ± 12.07 (1.62-44.98)
   B lymphocyte count, mean ± SD, (cells/µL) 247.65 ± 293.74 (13.10-1268.40)
Disease activity
  SLEDAI-2K, mean ± SD 11.75 ± 9.31(0-46)
  PGA, mean ± SD 1.66 ± 0.87 (0-3)
Previous treatments, n (%)
  Glucocorticoid 48 (85.7)
  Hydroxychloroquine 41 (73.2)
  Immunosuppressants 33 (58.9)
   MMF 20 (35.7)
   TAC 14 (25.0)
   CTX 9 (16.1)
   CsA 8 (14.3)
   LEF 6 (10.7)
   MTX 5 (8.9)
   Tripterygium glycosides 1 (1.8)
   AZA 1 (1.8)
  Biologics 15 (26.8)
   RTX 11 (19.6)
   Belimumab 5 (8.9)
   Telitacicept 2 (3.6)

SD, standard deviation; SEM, standard error of the mean; MMF, Mycophenolate mofetil; TAC, Tacrolimus; CTX, Cyclophosphamide; CsA, Cyclosporine A; LEF, Leflunomide; MTX, Methotrexate; AZA, Azathioprine; RTX, Rituximab; ELASA, Enzyme-Linked Immunosorbent Assay; RIA, Radioimmunoassay.

In the Abstract, two percentages were reported incorrectly in the first sentence of the Results section. This has been corrected to read:

“At baseline, 35.7% of patients were newly diagnosed, 55.4% had relapsing/refractory disease, and 8.9% were on maintenance therapy.”

A correction has been made to section Results, paragraph 2, to change “Besdieds” to “Besides”:

“Besides, antidsDNA antibody levels decreased, while complement levels exhibited a notable upward trend throughout the follow-up period.”

A correction has been made to section Results, paragraph 2, to change maitained” to “maintained”:

“Subgroups analysis revealed that all three subgroups, especially the new-onset and relapsing/refractory groups, showed a rapid decrease in SLEDAI-2K scores, which were maintained at low levels through week 48.”

The original version of this article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Edited and reviewed by: Luis Ignacio Gonzalez-Granado, University Hospital October 12, Spain